uniQure (NASDAQ:QURE) Sets New 1-Year High – Here’s Why

uniQure (NASDAQ:QURE)’s share price reached a new 52-week high on Tuesday . The stock traded as high as $19.00 and last traded at $18.88, with a volume of 109599 shares traded. The stock had previously closed at $18.08.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on QURE. The Goldman Sachs Group lifted their price objective on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 12th. Royal Bank of Canada increased their price objective on shares of uniQure from $14.00 to $20.00 and gave the company an “outperform” rating in a research report on Wednesday, December 11th. Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $20.00 to $52.00 in a report on Tuesday, December 10th. Wells Fargo & Company upgraded shares of uniQure from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 10th. Finally, Stifel Nicolaus boosted their price objective on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a report on Monday, December 16th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, uniQure presently has a consensus rating of “Moderate Buy” and an average target price of $33.88.

uniQure Trading Down 9.8 %

The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The company has a market cap of $775.99 million, a P/E ratio of -3.21 and a beta of 0.41. The stock’s 50-day moving average is $11.03 and its two-hundred day moving average is $7.90.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. The firm had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. As a group, equities research analysts predict that uniQure will post -3.82 earnings per share for the current fiscal year.

Insider Buying and Selling at uniQure

In other news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the transaction, the chief executive officer now owns 597,915 shares in the company, valued at $4,562,091.45. This trade represents a 0.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 4.74% of the company’s stock.

Institutional Investors Weigh In On uniQure

Hedge funds and other institutional investors have recently modified their holdings of the stock. RTW Investments LP bought a new stake in uniQure during the 3rd quarter worth approximately $49,000. China Universal Asset Management Co. Ltd. raised its position in shares of uniQure by 57.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 3,663 shares during the period. Atria Investments Inc bought a new position in uniQure in the 3rd quarter worth $53,000. Quarry LP purchased a new stake in uniQure in the 3rd quarter worth $58,000. Finally, Vanguard Personalized Indexing Management LLC raised its holdings in uniQure by 21.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 2,306 shares during the period. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.